secwatch.observer — SEC 8-K summary
======================================

Issuer:     Turn Therapeutics Inc. (TTRX)
CIK:        0002023016
Form:       8-K
Filed at:   2026-07-07T12:05:25+00:00
Accession:  0001213900-26-075757
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Turn Therapeutics Announces Final Stage 2 Design and Expansion of GX-03 Phase 2 Trial
--------------------------------------------------------------------------------

- Interim analysis of GX-03 Phase 2 trial in atopic dermatitis showed Week 4 vIGA-AD Success 71.4% vs 33.3% vehicle in EASI 1.1-7.0 subgroup.
- Final Stage 2 design will enroll 120-135 patients across full EASI spectrum (≥1.1) using Hochberg multiple testing procedure for four endpoints.
- GX-03 demonstrated favorable safety with no treatment-related serious adverse events or discontinuations reported.
- Company expects to complete enrollment in Q4 2026 and is capitalized through Q3 2027.
- Turn Therapeutics hosted an investor webcast on July 7, 2026 at 4:30 PM ET to discuss the results.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2023016/000121390026075757/0001213900-26-075757-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2023016/000121390026075757/ea0297061-8k_turn.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-075757

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer